Impact of first-line systemic therapy with atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.
Toshifumi TadaTakashi KumadaAtsushi HiraokaMasashi HirookaKazuya KariyamaJoji TaniMasanori AtsukawaKoichi TakaguchiEi ItobayashiShinya FukunishiKunihiko TsujiToru IshikawaKazuto TajiriHironori OchiSatoshi YasudaHidenori ToyodaChikara OgawaTakashi NishimuraTakeshi HatanakaSatoru KakizakiNoritomo ShimadaKazuhito KawataFujimasa TadaHideko OhamaKazuhiro NousoAkihiro MorishitaAkemi TsutsuiTakuya NaganoNorio ItokawaTomomi OkuboTaeang AraiMichitaka ImaiHisashi KosakaAtsushi NaganumaTomomitsu MatonoYohei KoizumiShinichiro NakamuraMasaki KaiboriHiroko IijimaYoichi Hiasanull nullPublished in: Journal of gastroenterology and hepatology (2023)
The use of Atezo/Bev as first-line systemic therapy in patients with HCC is expected to prolong survival.